BioLineRx Prices $3.75M Registered Direct Offering with Warrant Amendment
BLRX is trading near its 52-week low of $2.15 (2.8% above the low) on light trading volume (0.1× avg).
Summary
BioLineRx priced a $3.75 million registered direct offering at $2.78 per ADS, with warrants to purchase up to 2.02 million additional ADSs and an amendment to existing warrants lowering their exercise price to $2.78.
Key Events · Financing and Capital Events · BLRX
-
Registered Direct Offering Priced
1,348,921 ADSs sold at $2.78 per ADS, raising $3.75 million in gross proceeds before fees.
-
Concurrent Private Placement of Warrants
Warrants to purchase up to 2,023,382 ADSs issued at $2.78 per ADS, with exercise price of $2.78 and five-year term.
-
Warrant Amendment
Existing warrants to purchase 277,273 ADSs amended to reduce exercise price to $2.78 and extend expiration to August 31, 2031.
-
ATM Facility Reduced to Zero
Concurrent with the offering, the company reduced the maximum aggregate offering amount of its ATM Facility to zero.
Analysis · BLRX · Life Sciences
BioLineRx raised $3.75 million through a registered direct offering of 1.35 million ADSs at $2.78 per share, alongside a concurrent private placement of warrants to purchase up to 2.02 million additional ADSs. The deal includes a warrant amendment that reduces the exercise price on 277,273 previously issued warrants to $2.78 and extends their expiration to 2031. The offering price represents a modest discount to the last close, and the company is trading near its 52-week low, suggesting the capital raise comes from a position of relative weakness. The proceeds will fund R&D and working capital as the company advances its lead asset GLIX1.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLRX was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.